POSC399 Treatment Effect and Costs of the Complete Therapeutic Pathway in Patients with First-Line Castration-Resistant Prostate Cancer with Either First-Line Docetaxel or Abiraterone Acetate Plus Prednisone

Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.1300
https://www.valueinhealthjournal.com/article/S1098-3015(21)03095-3/fulltext
Title : POSC399 Treatment Effect and Costs of the Complete Therapeutic Pathway in Patients with First-Line Castration-Resistant Prostate Cancer with Either First-Line Docetaxel or Abiraterone Acetate Plus Prednisone
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)03095-3&doi=10.1016/j.jval.2021.11.1300
First page :
Section Title :
Open access? : No
Section Order : 10839
Categories :
Tags :
Regions :
ViH Article Tags :